Neurological Biomarkers Market Size and Forecast 2024-2033|Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Thermos Fisher Scientific Inc

The Neurological Biomarkers Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Neurological Biomarkers Market:

https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report

According to The Business Research Company’s Neurological Biomarkers Global Market Report 2024, The neurological biomarkers market size has grown rapidly in recent years. It will grow from $9.46 billion in 2023 to $10.63 billion in 2024 at a compound annual growth rate (CAGR) of 12.4%. The growth in the historic period can be attributed to increasing prevalence of neurological disorders, aging population, drug development needs, increased funding for neurological research, personalized medicine.

The neurological biomarkers market size is expected to see rapid growth in the next few years. It will grow to $17.18 billion in 2028 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to biomarkers for early detection, biosensors, wearable devices, global health initiatives, patient-centric approach. Major trends in the forecast period include technological innovation in imaging, rapid advances in omics technologies, integration of artificial intelligence (ai), real-world evidence in biomarker validation, advancements in diagnostic technologies, collaboration between industry and research institutions.

The increasing prevalence of neurological diseases is expected to propel the growth of the neurological biomarker market going forward. Neurological illnesses affect the brain, spinal cord, and all of the body’s other nerves. Parkinson’s disease is a neurodegenerative disorder affecting the neurological system and the areas of the body that are under the control of the nerves. Neurological biomarkers help provide an early diagnosis of Parkinson’s disease using pathological, biochemical, and genetic testing. For instance, in December 2022, according to the Parkinson’s Foundation, a US-based non-profit organization, the number of new diagnoses of Parkinson’s disease reached 90,000 in 2022, up from 60,000 per year in 2021. Therefore, the increasing prevalence of neurological diseases is driving the growth of the neurological biomarker market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=12677&type=smp

The neurological biomarkers market covered in this report is segmented –

1) By Product: Proteomics Biomarker, Genomics Biomarker, Metabolomics Biomarker, Imaging Biomarker, Other Products

2) By Application: Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, Schizophrenia, Depression, Multiple Sclerosis, Spinal Muscular Atrophy

3) By End-User: Hospital Laboratories, Clinical Diagnostic Centers, Research Organizations, Other End-Users

Major companies operating in the neurological biomarkers market are forming partnerships to develop new products and strengthen their positions in the market. Collaborations and partnerships in the neurological biomarkers market foster innovation, leverage complementary expertise, and accelerate the development and commercialization of advanced therapies by combining resources and capabilities. For instance, in July 2022, NeuroSense Therapeutics Ltd., an Israel-based company developing treatments for severe neurodegenerative diseases partnered with NeuraLight, an Israel-based company developing objective and sensitive biomarkers for neurological disorders. This collaboration is to identify oculometric indicators for Amyotrophic Lateral Sclerosis (ALS) through the application of AI (Artificial Intelligence) and ML (Machine Learning). The partnership, which comes after NeuraLight’s $25 million Series A financing, is to enhance the discovery and application of ALS digital indicators in a parallel study. This will be the collaboration’s first clinical trial. The partnership is centered on the application of oculometric digital indicators, which may allow for patient classification and boost clinical trial success rates.

The neurological biomarkers market report table of contents includes:

1. Executive Summary

2. Neurological Biomarkers Market Characteristics

3. Neurological Biomarkers Market Trends And Strategies

4. Neurological Biomarkers Market – Macro Economic Scenario

5. Global Neurological Biomarkers Market Size and Growth

26. South America Neurological Biomarkers Market

27. Brazil Neurological Biomarkers Market

28. Middle East Neurological Biomarkers Market

29. Africa Neurological Biomarkers Market

30. Neurological Biomarkers Market Competitive Landscape And Company Profiles

Top Major Players: